|drug3519||Transfusion of SARS-CoV-2 Convalescent Plasma. Wiki||1.00|
|drug2517||Placebo 0.9% NaCl solution Wiki||1.00|
|drug3520||Transfusion of standard Plasma. Wiki||1.00|
|D014777||Virus Diseases NIH||0.11|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The world is currently experiencing a coronavirus (CoV-2) pandemic. A new (SARS)-CoV infection epidemic began in Wuhan, Hubei, China, in late 2019; originally called 2019- nCoV the virus is now known as SARSCoV- 2 and the disease it causes COVID-19. Previous CoV epidemics included severe acute respiratory syndrome (SARS)-CoV, which started in China in 2003 and Middle East respiratory syndrome (MERS)-CoV in the Middle East, which started in 2012. The mortality rates were >10% for SARS and >35% for MERS. The direct cause of death is generally due to ensuing severe atypical pneumonia and ensuing acute respiratory distress syndrome (ARDS). Pneumonia also is generally the cause of death for people who develop influenza, although the mortality rate is lower (1%-3% for the influenza A H5N1 pandemic of 1918-1919 in the United States). Risk factors for a poor outcome of SARS-CoV-2 infection have so far been found to include older age and co-morbidities including chronic cardiovascular and respiratory conditions and current smoking status. In May 2020, the FDA authorized the emergency use of remdesivir for treatment of COVID-19 disease based on topline date of two clinical trials, even though an underpowered clinical trial did not find significant improvement in COVID- 19 patients treated with remdesivir. Nevertheless, remdesivir is the first and so far, only approved treatment for COVID-19. Additionally further trials and clinical observations have not found a significant benefit of other antiviral drugs. Although the results of several studies are still pending, there is still a desperate need for an effective, safe treatment for COVID-19. Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS. Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it reduces inflammation.
Description: Time to clinical improvement of a decrease of at least two points on a seven-point ordinal scale of clinical status or discharged alive from hospital. The seven-point scale consists of the following categories: not hospitalized; hospitalized, not requiring supplemental oxygen; hospitalized, requiring supplemental oxygen; hospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; hospitalized, intubation and mechanical ventilation; ventilation and additional organ support - pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO); deathMeasure: time to clinical improvement Time: Randomization until discharge from hospital but up to maximum 28 days
Description: Frequency of Patient who need mechanical ventilation during hospital stayMeasure: Frequency of mechanical ventilation Time: Randomization until discharge from hospital up to maximum 28 days
Description: Frequency of Patient who showed a multi organ dysfunction Syndrome during Hospital stayMeasure: Frequency of Multi organ dysfunction Syndrome (MODS) Time: Randomization until discharge from hospital up to maximum 28 days
Description: Blood pressure will be assessed daily in mmHgMeasure: Blood pressure Time: Daily until discharge up to maximum 28 days
Description: Heart rate will be assessed daily in bpmMeasure: Heart rate Time: Daily until discharge up to maximum 28 days
Description: Respiratory rate will be assessed daily in Counts per minuteMeasure: Respiratory rate Time: Daily until discharge up to maximum 28 days
Description: Body temperature (auricular) will be assessed daily in °CMeasure: Body temperature (auricular) in °C Time: Daily until discharge up to maximum 28 days
Description: Pulse oximetry will be assessed daily in %Measure: Pulse oximetry Time: Daily until discharge up to maximum 28 days
Description: Glasgow Coma Scale will be assessed daily The lowes possible score is 3 = deep coma or death The highest possible score is 15 = Fully awakeMeasure: Glasgow Coma Scale Time: Daily until discharge up to maximum 28 days
Description: Visual analogue scale for dyspnea and cough as patient-related outcome parameterMeasure: Dispnea and caugh Time: Randomization until discharge from hospital up to maximum 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports